drugset / Trial / NCT01327066
Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin in healthy male and female subjects.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-04
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Droxidopa | Small molecule | 600 mg | Oral |
| Subject | Droxidopa | Small molecule | 2000 mg | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.